Monday, September 19, 2016

Sarepta's keenly watched muscle dystrophy drug wins FDA approval

Sept 19 (Reuters) - Sarepta Therapeutics Inc's

Duchenne muscular dystrophy drug won approval from the U.S. Food

and Drug Administration on Monday, capping months of regulatory

uncertainty and...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)